Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination - Top-Institutions - MDSpire

Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination

  • By

  • Alfred J. Simmons

  • Anna S. Nikonova

  • Chloe D. Jonas

  • Katherine A. Pniewski

  • Deepak Upreti

  • Maria I. Perez

  • Satish Adhikari

  • June 4, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Immunotherapy
    • Cancer Vaccination

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Cancer Immunotherapy

  • #3

    Broad Institute
    Broad Institute

    Cambridge, Massachusetts

    Key Differentiators

    • Genomics
    • Oncology

Original Source(s)

Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination

  • by Alfred J. Simmons, Anna S. Nikonova, Chloe D. Jonas, Katherine A. Pniewski, Deepak Upreti, Maria I. Perez, Satish Adhikari

  • June 4, 2026

Related Content

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee

The intratumoral microbiome: a review of the tumor microenvironment’s fourth axis shaping anti-tumor immunity, cancer prognosis, and therapeutic response

Successful conversion therapy for presumed granulocyte colony-stimulating factor–producing hepatocellular carcinoma: a case report